Bioengineered Protein Drugs Market is Expected to Reach US$ 336.9 Billion by 2025; Increasing Drugs in Phase III of Clinical Trials to Fillip Market

Bio engineered proteins drugs are synthesized through genetic engineering for treatment of human injury, systemic treatments of cancers, organ transplants etc. They are also known as Recombinant Protein drugs and are used for modification of immune reactions, through pathophysiological pathways at multiple levels of cells adhesion and activation. Rise in number of bioengineered protein drugs for treatment of various diseases along with increase in prevalence of diseases such as infectious diseases, cancer, diabetes, etc., are the major reasons for the expansion of the bioengineered protein drugs market. Bioengineered protein drugs are expensive; however, due to their lesser or no side effects, which can also be reversed once the patient treatment stops, the market for these drugs is estimated to expand. Moreover, these drugs when compared with alternative therapies prove to be more efficacious. This further increases the demand for these drugs. However, rise in the development of biosimilars is posing a threat for the development of the market globally.

The global Bioengineered Protein Drugs Market was valued at US$ 177.7 Bn in 2016 and is estimated to reach US$ 336.9 Bn in 2025 at a CAGR of 7.4% from 2017 to 2025.

Inquire for a Sample Copy of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=8188

The bioengineered protein drugs market by drug type has been segmented as monoclonal antibodies, therapeutic proteins and vaccines. The therapeutic proteins segment accounted for the largest share of the global bioengineered proteins drugs market in 2016 due to extensive activities in the therapeutic protein engineering and recombinant DNA technology products. The Centers for Disease Control and Prevention has estimated that nearly 48.7% people globally use at least one therapeutic proteins prescribed drug. High patient preference has increased market share of the segment in the past few year. However, rising hormonal disorders, diabetes, and infertility have driven demand for recombinant vaccines. Nearly 97% of the vaccines require cold storage of 2°C–8°C from manufacturing until end delivery. Lack of access to properly stored vaccines lead to 2.4 million deaths every year due to vaccine-preventable diseases. Extensive research has demonstrated improvement in temperature stability of vaccines. These factors are likely to contribute to the growth of the vaccine segment in the near future. The monoclonal antibodies segment is projected to expand at a significant but relatively slow growth rate during the forecast period due to long production process.

The monoclonal antibody segment has been further categorized as Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis and others. Likewise, therapeutic protein segment further categorized as hormones, cytokines, blood factors, enzyme therapy, thrombolytics, others. Neupogen, Neulasta, interferon alpha, erythropoietin alpha, interleukin and others are included in the cytokines category. tPA, streptokinase and urokinase has been included in the thrombolytics category. Syetemic enzyme therapy and digestive enzyme therapy are the two types of enzyme therapy.

On the basis of the disease condition, the market has been segmented into cancer, diabetes, autoimmune disorder, infectious disease, hematopoiesis, CVD, neurodegenerative and others. The cancer segment accounted for a major share of the market in 2016. However, the infectious disease segment is anticipated to record a rapid growth rate during the forecast period. Rising mortality due to cancer has led to an increase in focus for the development of effective innovative drugs and products to combat the situation. Cancer-related deaths globally per year is almost 7 million people and the number is projected to reach 16 million by 2020. Thus, cancer is considered a highly prosperous disease condition by pharmaceutical giants. The engagement of bioengineered proteins drugs with cell membrane receptors is one of the additional factor contributing for major share in this segment. Further, the novel possibilities ensuring the maximum efficacy and minimal side effects offered by endocytosis has led the demand for the target specifics bioengineered proteins drug in this segment. However, the infectious disease segment is anticipated to expand at a high CAGR during the forecast period owing to high demand (especially developing nations) and rise in development of vaccines.

By end-user market is categorized into pharma and biotech companies, CROs and research institutes. The pharmaceutical companies and biotechnological companies segment held major share of the global bioengineered proteins drugs market in 2016. However, the contract research organizations segment is anticipated to expand at a high CAGR during the forecast period. Most companies prefer in-house production in case of exclusive drugs or when the production is limited to a specific geography. An increase in sales has been observed in pharmaceutical companies and biotechnological companies during the recent year but there is considerable drop in profit margins. This is due to increasing price, cost pressure, regulatory changes, and patient expiry. Despite the rise in research and development cost, the decrease in the number of new products is a growing issue for pharmaceutical companies and biotechnological companies, which is driving the market growth of contract research organizations.

Major players operating in the global bioengineered protein drugs market includes Abbott Laboratories, Amgen, Inc., Bayer AG, Biocon Ltd., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fresenius Kabi, GlaxoSmithKline plc, Johnson & Johnson (Janssen), Merck & Co., Inc., Novartis AG, Panacea Biotec, ProBioGen AG, Reliance Life Sciences Pvt. Ltd. and Sanofi.

Read Report with Complete TOC – http://www.transparencymarketresearch.com/bioengineered-proteins-drugs-market.html

Name: Rohit Bhisey
Organization: Transparency Market Research

ReleaseID: 8088